Hubbry Logo
Cochlear LimitedCochlear LimitedMain
Open search
Cochlear Limited
Community hub
Cochlear Limited
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cochlear Limited
Cochlear Limited
Cochlear Limited
View on Wikipedia
from Wikipedia

Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.[3]

Key Information

Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate.[4][5] As of 2022, the company holds 50% of the cochlear implant market,[6] with more than 250,000 people receiving one of Cochlear's implants as of 2015.[3]

Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003,[7] and one of the world's most innovative companies by Forbes in 2011.[8]

History

[edit]

Corporate affairs

[edit]

Cochlear was originally founded in 1981 as a subsidiary of Nucleus, a medical electronics company founded in 1964. Previously in 1981 Nucleus received a grant from the Australian government to commercialize development of a multi-channel cochlear implant like the one that Graeme Clark created. The project was a success, with the first commercial implantation of a Nucleus implant taking place in 1982.[9] Although it was established as a subsidiary of Nucleus, which was acquired by Pacific Dunlop in 1988, Cochlear soon became a separate and publicly listed company in 1995 when Pacific Dunlop was split up. In 2004 Cochlear expended its portfolio beyond cochlear implants by buying Entific Medical Systems, a Swedish company that produced bone anchored hearing aids for conductive hearing loss. Most of the company's income is from after-market (post-implantation) products such as processor upgrades and accessories.[10][11][12][a]

In April 2022, Cochlear announced it would acquire Danish competitor Oticon Medical for A$170 million after its parent company Demant decided to exit the hearing implant business. At the time, Oticon Medical was running at a loss, with sales lower than expected and technical problems affecting some of their devices, leading to a voluntary recall.[13][14]

Violation of anti-kickback statute

[edit]

Cochlear Limited's 2007 annual report acknowledged that a US Federal investigation continued into its payments to physicians and providers. In February 2007, part of the whistleblower complaint against Cochlear filed by former vice president and director at Cochlear Americas Brenda March was unsealed by the U.S. District Court for the District of Colorado. The complaint alleges that Cochlear violated the Federal anti-kickback statute through its Partners Program, which offered credits towards free or discounted products for physicians who implanted Cochlear devices, as well as gifts, trips, and other gratuities paid to physicians and providers. The government intervened in the case and transferred it from the U.S. Department of Justice to the Health and Human Services Inspector General for the imposition of civil penalties. In June 2010, Cochlear America agreed to pay a fine of $880,000 as part of a settlement with the US Department of Justice.[15][16][17]

Historic products

[edit]

Cochlear implants

[edit]

Implants

[edit]

CI22M (Nucleus 22) implant received FDA approval in 1985, making it the first FDA-approved multi-channel cochlear implant.[18][19][20] While first approved for postlingually deaf adults,[21] its FDA approval expanded to people ages two and up in 1990 after clinical trials on children.[22][23][24][25]

In 1998 FDA approved the company's first Nucleus 24 family implant, the CI24M, which was the first cochlear implant to have a removable magnet to make it easier for patients to get an MRI. Nucleus 24 implants had and 10 contacts.[26] The next version of the Nucleus 24 to be approved by the FDA the CI24R implant, which came with the option of three different styles of electrode array. In 2005 the FDA approved the CI24RE "Freedom" implant, which had a new chip that reduced power consumption and better stimulation for improved sound processing. The implant had two options for the electrode array, both from the previous version of the CI24R "contour" options.[27][28][29][25]

The CI500 implant range, which had 22 contacts enabling detection of 161 frequencies, was launched in 2009. When the whole CI500 family was recalled in 2011 due to soft failures of some CI512 implants, the CI500 family consisted of the CI512 and CI513 cochlear implants, the CI522, CI532 which had a perimodular electrode array, CI551 which had a double array, and the Nucleus ABI 541, which was an auditory brainstem implant version of the product.[30][31]

In the mid to late 2000s, the company released its first short-electrode Hybrid implants, starting off with the Hybrid S8 and Hybrid S12; the devices were used in clinical trials and research on the potential for use in patients with severe to profound high-frequency hearing loss but significant low-frequency residual hearing. All Hybrid implants were paired with a sound processor fitted with an accompanying acoustic piece to amplify the lower frequencies in the recipient's residual hearing. Eventually, in 2014 the FDA approved the Nucleus L24 "Hybrid" implant (CI24REH) for use in people ages 18 and up.[32][33]

The Nucleus Profile implant, approved by the FDA in summer 2015, succeeded the Nucleus 24 implant. At the time it was released, it was the thinnest cochlear implant on the market. However, the titanium case on the Profile implant was 2.5 times stronger than the previous Nucleus 24 implant. Just like its predecessor, a variety of electrode array options were available the Nucleus Profile.[34]

Sound processors

[edit]
Body-worn
[edit]

The first sound processors made by the company were quite primitive compared to modern behind-the-ear and off-the-ear processors. The first sound processor made for the Nucleus 22 was the Wearable Sound Processor (WSP), an analog device that was only worn by adults; three versions of it were produced. Eventually, in 1989 it was replaced by the Mini Speech Processor, a slightly smaller body-worn digital processor. Subsequently in 1994 the company released the Spectra processor, which continued to improve audio processing, and became the last body-worn processor designed specifically for the Nucleus 22, as all later processors were made backwards-compatible with Nucleus 22 implants (meaning that the version of those processors were first released were compatible with newer implants and that only later were versions of those processors compatible with the Nucleus 22 were produced). In 1997 the company released the SPrint processor which had a small screen on it, and was compatible with the newly-developed Nucleus 24 implants, which received FDA approval in 1998. The SPrint became the last body-worn processor offered by the company; no Nucleus 22 version of it was made since the processor was made obsolete by the ESPrit that same year.[35][36][37]

Behind-the-ear
[edit]

In 1998 the company released its first processor that lacked a body-worn component, the ESPrit. However, the original ESPrit was only compatible with the Nucleus 24 implants, so in 2001 the ESPrit 22, which looked nearly identical to the ESPrit, was released for patients with older Nucleus 22 implants.[38]

In 2002 the company released the ESPrit 3G for Nucleus 24 implants. It was the first processor equipped with telecoil, allowing streaming of audio wirelessly from certain sources such as phones and sound systems that were telecoil compatible. Later a version for older Nucleus 22 implants was released.[39][40][41][42]

In 2005 the company released the Nucleus Freedom sound processor. Unlike previous processor upgrades, the Freedom was larger than its predecessor. Nevertheless, it had more sophisticated sound processing technology than the ESPrit 3G.[43] While the previous ESPrit 3G and the earlier ESPrit required the use of disposable batteries,[39] the Nucleus Freedom was the company's first behind-the-ear processor that offered a rechargeable power supply option.[44][45] However, it was not until 2008 that a version of the Nucleus Freedom processor compatible with N22 implants was released.[46]

A Nucleus Freedom sound processor fitted with an acoustic earhook to enable EAS
A Nucleus Freedom sound processor fitted with an acoustic earhook to enable EAS

An electric acoustic stimulation (EAS) or "hybrid" version of the Freedom sound processor that included an earhook with an acoustic component provided amplification of sounds that could be picked up by residual hearing was used in clinical trials of early Nucleus Hybrid S8 and S12 implants, making it the first Cochlear processor that capable of EAS.[47][48]

The Nucleus 5 (CP800 series) sound processor was approved by the FDA in 2009. Despite being much smaller than its predecessor, it also had more sophisticated sound processing capability. Initially released with the CI500 series implant, it was eventually made compatible with the earlier Nucleus 24 series implants.[43][49]

The Nucleus 6 (CP900 series) was released in 2013; while it looked very similar to the Nucleus 5 and contained many of the same features, it was slightly smaller and had more advanced computer chip. Both the Nucleus 5 and Nucleus 6 shared many of the same outward features, such as a direct audio input port, dual omnidirectional microphones, three battery options (rechargable, compact rechargeable, and disposable), and many similar or even identical accessories. The Nucleus 6 was backwards compatible with all Nucleus implants at the time, from the current generation to the Nucleus 22.[50][51]

One-piece
[edit]

In 2016 the company released the Nucleus Kanso processor, first one-piece sound processor made by the company. The electronics in and features of the device were nearly identical as in the previous Nucleus 6. However, because of its size and positioning, it is more easily concealed by hair or a hat.[52][53][54]

Accessories

[edit]
A Nucleus 6 sound processor equipped with an FM receiver (in light brown)

In 2013 Cochlear released the "Aqua Accessory", a sealable single-use plastic pouch shaped to fit a Nucleus 5 processor. When used properly, it gave an IP68 water resistance level to the processor inside. However, it soon became obsolete by the 2014 introduction of the Aqua+ kit, which consisted of a waterproof coil and a silicone sleeve for the processor unit.[55][56][57]

Other accessories include a TV streamer using ReSound technology that allows streaming of audio directly to sound processor, a wireless mini mic that can be worn be the person speaking with the implant user, and a wireless phone clip for streaming audio from a bluetooth-enabled device to the sound processor.[58][59]

Various sound processor models have been designed to be compatible with certain FM receivers made by other companies specifically for use in the given sound processor. For example, the Phonak Roger 20 made by Phonak is compatible with the Nucleus 7, where the receiver can be connected between the processing unit and the battery pack. However, the previous Roger 14 that was used with Nucleus 5 and Nucleus 6 devices was plugged into the side of the processor unit (pictured). Other earlier processors like the ESPrit and Freedom also had FM options.[60][61][62]

Bone anchored hearing aids (BAHA)

[edit]
Main article: Cochlear Bone Anchored Solutions

Auditory brainstem implants (ABI)

[edit]

The company also produces auditory brainstem implants, which look similar to cochlear implants but bypass the cochlea completely, instead placing a rectangular electrode array on the cochlear nucleus of the brainstem. The first ABI made by the company was the Nucleus 22ABI, released in the early 1990s. It had eight electrodes, utilized parts from the Nucleus 22 cochlear implant, and utilized the Spectra sound processor. This was followed by the 1999 introduction of an improved ABI based on the Nucleus 24, the Nucleus ABI24, which had 21 electrodes and allowed for more advanced audio processing in addition to having a removable magnet; in 2000 it was approved by the FDA for use in people with Neurofibromatosis Type 2 ages 12 and older. In 2016 the Nucleus Profile ABI541 received FDA approval.[63][64][65][66][28]

Modern systems

[edit]

As of 2022, the latest cochlear implant is the Nucleus Profile Plus implant, which can withstand a 3.0 Tesla MRI without having the magnet removed or needing a headwrap. In 2019, the Osia OSI200 osseointegrated steady-state implant and the accompanying Osia 2 sound processor were also approved. Earlier in 2013, the FDA approved the BAHA BI300 implant as part of the BAHA Attract system; the device is also incorporated in the Osia system.[67][68][69][70]

As of 2022, the current behind-the-ear cochlear implant sound processor is the Nucleus 7 (CP1000 series), which was released in 2017. It is smaller and lighter than the Nucleus 6, and can stream audio directly from certain Apple devices without the need for an additional device; however, users with Android phones have to use the phone clip accessory to stream audio to the Nucleus 7. The Nucleus 7 also has a battery life that is 50% longer than the Nucleus 6. The processor can also be controlled via a downloadable phone app instead of a separate remote control, although a separate remote control is available. The Nucleus 7 is also compatible with a bimodal hearing system (the use of a cochlear implant in one ear and a hearing aid in the other). If the user has a ReSound Enzo 3D or Lynx 3D hearing aid in their non-implanted ear, they can stream audio from certain sources such as compatible Apple devices to both ears at the same time. However, the device does not have a port for direct auditory input. Like its predecessors, a version of it with an acoustic receiver for EAS is available. It is compatible with all generations of nucleus implants.[71][72]

The company released the Nucleus 8 in summer 2022, but it is not expected to be available to most recipients until 2023.[73][74]

The other modern sound processor for cochlear implants is the Kanso 2, which was released in 2020; it is compatible with the same app and accessories as the Nucleus 7 and is smaller than the original Kanso. However, unlike the Nucleus 7, there is no EAS option due to it being an off-ear device, and it is compatible with the original Nucleus 22 implant.[75][76]

In 2021 the company released the BAHA 6 Max Sound Processor for users of BAHA implants; it was smaller than the previous generation processor.[77]

Recalls

[edit]

Cochlear recalled some of its CI22M (Nucleus 22) implants in 1995 due to failures with the internal power supply caused by the capacitors being installed backwards, however less than 10 devices had to be explanted.[78][79]

On 12 September 2011, Cochlear announced that they were voluntarily recalling all Nucleus CI500 implants after reports of the devices shutting down.[80][81] The cause of the malfunction and number of devices affect is unknown, however, no patients suffered injuries from the device failures, and the company want back to the CI24RE implant until launching a replacement in 2013.[82] The CEO said in a press conference that manufacturing of those devices would cease until the cause of the malfunction is evaluated.[83] Representatives of the company further elaborated that the reason for the recall being that they did not want to suffer more failures that could hurt the reputation of the company.[84] The recall resulted in a drop of 27% of the companies shares, as the product being recalled made up 70% of Cochlear's total company sales.[85]

Union relations

[edit]

Fair Work Australia issued bargaining orders against Cochlear Limited in relation to breaching good faith bargaining requirements under the Fair Work Act after a long bargaining battle. Workers at the company's Sydney manufacturing facility in Australia, represented by the Australian Manufacturing Workers Union, had been attempting to bargain with Cochlear starting 2007 after the company tried to switch to individual contracts. Majority vote of workers supported collective bargaining, but negotiations went to a standstill for a while, and the union accused Cochlear of not engaging in good-faith negotiations.[86]

[edit]
  • early 1980s wearable sound processor with headset
    early 1980s wearable sound processor with headset
  • 1989 Mini Speech Processor
    1989 Mini Speech Processor
  • 1994 Spectra body-worn processor
    1994 Spectra body-worn processor
  • 1997 SPrint body-worn processor
    1997 SPrint body-worn processor
  • 1998 ESPrit
    1998 ESPrit
  • 2002 ESPrit 3G
    2002 ESPrit 3G
  • 2005 Nucleus Freedom
    2005 Nucleus Freedom
  • 2009 Nucleus 5
    2009 Nucleus 5
  • 2013 Nucleus 6
    2013 Nucleus 6
  • 2016 Nucleus Kanso 1
    2016 Nucleus Kanso 1
  • 2017 Nucleus 7
    2017 Nucleus 7
  • 2020 Kanso 2
    2020 Kanso 2
  • 2022 Nucleus 8
    2022 Nucleus 8

See also

[edit]

Footnotes

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cochlear Limited

View on Grokipedia
from Grokipedia

Cochlear Limited is an Australian medical technology company headquartered in Sydney, specializing in implantable hearing solutions for individuals with severe to profound hearing loss. Founded in 1981 as a subsidiary of Nucleus Limited to commercialize the multi-channel cochlear implant pioneered by Professor Graeme Clark at the University of Melbourne, the company has grown into the global leader in its field, providing devices that have enabled over 700,000 people worldwide to hear.
The company's core products include the Nucleus cochlear implant systems, Baha bone conduction implants, and the Osia system, along with associated external sound processors that convert sound into electrical signals stimulating the auditory nerve. Cochlear maintains a dominant market position, with over 60% share in cochlear implants as of 2025, supported by a track record of innovation such as the first FDA-approved multi-channel implant and ongoing advancements in processor durability and connectivity. Its implants, first commercially implanted in 1982, represent a breakthrough in bionic hearing restoration, though the technology remains debated within some deaf communities for its implications on cultural identity despite empirical evidence of improved auditory perception and quality of life.

Company Overview

Founding and Core Mission

Cochlear Limited was established in 1982 by Professor Graeme Clark to commercialize the multi-channel , known as the bionic ear, which he pioneered at the . Clark's development stemmed from research initiated in 1967, culminating in the world's first successful multi-channel implantation in a human patient in 1978. The company originated as part of efforts to bring this technology from laboratory innovation to clinical and commercial application, with initial sales commencing in 1983 and formal incorporation following shortly thereafter. Clark's motivation was deeply personal, driven by the communication challenges faced by his father due to profound , which underscored the need for a device capable of electrically stimulating the cochlear nerve to restore . This foundational drive positioned Cochlear as a pioneer in implantable hearing technologies, transitioning from academic research to a dedicated enterprise focused on severe to profound . The core mission of Cochlear Limited is to help people hear and be heard by innovating and delivering implantable hearing solutions that empower individuals to connect with others and lead full lives. This purpose reflects Clark's vision of making cochlear implantation the for eligible patients, emphasizing lifelong hearing outcomes through reliable, evidence-based technologies.

Global Market Position and Financial Performance

Cochlear Limited holds a dominant position in the global market, commanding over 60% as of 2025 (FY25, ended June 30, 2025). The company is recognized as the leading manufacturer of cochlear implant devices, with developed markets accounting for approximately 80% of its revenue. Its portfolio extends to bone-anchored hearing aids and other auditory solutions, though cochlear implants remain the core revenue driver, benefiting from high due to technological complexity and regulatory approvals. Competitors such as and Advanced Bionics trail with significantly lower shares, estimated at 25% and 20% respectively in historical data, underscoring Cochlear's entrenched leadership. In FY25, Cochlear reported sales revenue of A$2,356 million, a 4% increase from A$2,258 million in FY24, driven primarily by a 13% constant currency rise in revenue and approximately 10% growth in implant unit sales. Statutory net profit after tax rose 9% to A$389 million, reflecting operational efficiencies and product upgrades like the Nucleus 8 platform, despite headwinds from currency fluctuations and moderated services revenue growth. The company's underlying net profit guidance for FY26 projects 11-17% growth to A$435-460 million, supported by expansion and innovations in off-the-ear processors.
Fiscal YearSales Revenue (A$m)Net Profit After Tax (A$m)Key Growth Driver
FY231,936Not specifiedImplant volume recovery post-COVID
FY242,258Not specified15% revenue growth across units
FY252,35638910% implant units; constant currency implant sales up 13%
Cochlear's financial resilience is evident in its consistent margins, with operating margins around 26% in recent years, bolstered by a recurring services from upgrades and maintenance, though this segment declined 13% in FY25 due to prior-year comparatives. The firm's emphasizes R&D —approximately 10-12% of annually—to sustain market dominance amid a projected global market CAGR of 9% through 2030.

Historical Development

Origins and Early Innovations


Professor Graeme Clark began researching cochlear implants in 1967 at the University of Melbourne, driven by the profound deafness affecting his father and seeking to develop an implantable device to restore hearing. His work focused on creating a multi-electrode array to stimulate different parts of the cochlea, addressing limitations of prior single-channel attempts. After overcoming challenges in electrode design, biocompatible materials, and speech processing, Clark's team implanted the first prototype multi-channel cochlear implant on 1 August 1978 at the Royal Victorian Eye and Ear Hospital in Melbourne, with patient Rod Saunders reporting initial sound perception. The success of this implant prompted efforts to commercialize the technology, leading to the establishment of the Cochlear Project under Nucleus Limited in 1981, supported by funding. This initiative resulted in the incorporation of Cochlear Pty Ltd in 1983, which formalized as Cochlear Limited by 1985 to manufacture and distribute the devices. The first commercial recipient, Graham Carrick, received a Nucleus implant in 1982, marking the transition from research prototype to viable medical product. Early innovations centered on the Nucleus 22 system, launched in 1984 as the first commercial multi-channel , featuring 22 electrodes inserted into the scala tympani for frequency-specific stimulation. Paired with a wearable speech processor employing feature-extraction strategies, it improved speech discrimination over single-channel predecessors, gaining FDA approval for post-lingually deaf adults in 1985. These advancements laid the foundation for widespread adoption, emphasizing reliability and auditory nerve preservation during surgery.

Key Milestones and Expansion

Cochlear Limited was established in 1981 as a of Nucleus Limited in , focused on commercializing the multichannel developed by Graeme Clark. A pivotal early milestone occurred in 1982 when Graham Carrick received the world's first commercial Nucleus implant, initiating broader clinical use and establishing the foundation for the company's growth. After Nucleus was acquired by Pacific Dunlop in 1988, Cochlear operated with increasing autonomy and was floated on the Australian Securities Exchange in 1995, providing capital for expansion. To diversify beyond cochlear implants, the company acquired Swedish firm Entific Medical Systems in 2005, incorporating technology into its portfolio. Cochlear's global expansion accelerated with market entries such as in the mid-1990s, commemorated with 30 years of operations in 2025. Manufacturing capabilities grew through a new headquarters and facility in 2010, followed by a $50 million plant announced for in 2017 and a RM30 million expansion in in 2022 to address rising demand. These efforts have positioned Cochlear with operations in over 100 countries and a leading 60% share of the global market.

Corporate Governance and Operations

Cochlear Limited is governed by a Board of Directors comprising nine members as of 2025, including eight independent non-executive directors and one executive director, the Chief Executive Officer and Managing Director. The Board, chaired by Alison Deans, is responsible for setting strategic direction, overseeing management performance, ensuring robust governance frameworks, and safeguarding shareholder interests, while delegating day-to-day operations to the CEO. Key Board members include Dig Howitt (CEO and Managing Director), Caroline Clarke, Sir Michael Daniell KNZM, Michael del Prado, Richard Freudenstein, and Christine McLoughlin AM, selected for their expertise in areas such as healthcare, finance, and technology. The Board maintains independence through policies on director tenure, conflicts of interest, and external appointments, with regular evaluations of skills and performance to align with the company's focus on implantable hearing solutions. The executive leadership team, reporting to the CEO, drives operational execution across global regions. Dig Howitt has served as CEO and President since July 2017, overseeing strategy implementation with a 2024 compensation package of approximately A$4.63 million, comprising salary and performance incentives. Key executives include Dr. Sarah Thom (), Jan (), Stu Sayers (President, and , effective January 2025), and regional presidents managing sales, marketing, and clinical support in markets such as , the , and . Recent transitions include Richard Brook's departure as President of , , and at the end of December 2024 after 20 years, reflecting ongoing leadership evolution to support growth in emerging markets. Operationally, Cochlear maintains a global footprint with headquarters in , , and manufacturing facilities across multiple countries to ensure and localized production. Principal sites include and in for implant assembly and electronic components (with the facility, opened in 2018, employing around 200 staff); Mölnlycke, , for core implant manufacturing; , , expanded in 2022 to cover 50,000 square feet for sound processor production, logistics, and operations employing over 300 people; and Lacombe, , established in 2017 for implants and processors at a cost of A$50 million. Additional R&D and manufacturing occur in and , supporting a vertically integrated model that emphasizes under ISO standards and with bodies like the FDA and TGA. This distributed network mitigates risks from supply disruptions, as demonstrated in annual reports highlighting diversification post-global events like the .

Products and Technologies

Cochlear Implants

Cochlear Limited's cochlear implants, marketed under the Nucleus® brand, are surgically implanted devices that bypass damaged hair cells in the cochlea to electrically stimulate surviving auditory nerve fibers, enabling perception of sound in individuals with severe to profound bilateral sensorineural hearing loss. The system consists of an internal receiver/stimulator affixed to the skull behind the ear, connected to an electrode array inserted into the scala tympani of the cochlea, and an external speech processor worn on or off the ear that captures, processes, and transmits audio signals via radiofrequency to the implant. The Nucleus system pioneered multichannel stimulation, with Cochlear achieving the first FDA approval for a multichannel in the United States in 1985, allowing for finer pitch discrimination compared to single-channel predecessors. Early models, such as the 1982 wearable processor, evolved into behind-the-ear designs like the 1998 ESPrit and advanced to the 2005 Nucleus Freedom with contour electrode arrays for improved insertion and neural interface. Subsequent generations incorporated technologies like Advanced ' ClearVoice and Cochlear's SmartSound for and directional focus, enhancing speech understanding in complex environments. Current Nucleus implants offer arrays tailored to cochlear , including slim straight, perimodiolar, and lateral wall designs to accommodate variations in size and residual hearing preservation for hybrid electro-acoustic stimulation (EAS). The internal components support up to 22-24 channels for frequency-specific stimulation, with MRI-compatible magnets up to 3 Tesla in recent models like the CI632. External processors, such as the 2022 Nucleus 8, integrate connectivity, telecoil, and waterproofing for swimming up to 3 meters depth, while off-the-ear options like Kanso 2 provide aesthetic discretion. In June 2025, Cochlear launched the Nucleus Nexa , the first implant with internal data logging and upgradeable firmware via updates, potentially extending device longevity without reimplantation. Clinical indications include children as young as 9-12 months with limited benefit from hearing aids and adults post-lingual , with outcomes showing open-set in quiet settings for many recipients after rehabilitation; however, performance varies based on auditory preservation, duration of , and cognitive factors. Over 700,000 Nucleus implants have been performed globally as of 2023, positioning Cochlear as the market leader in cochlear implant systems.

Bone-Anchored Hearing Aids (BAHA)

Cochlear Limited entered the bone-anchored hearing aid market through its acquisition of Entific Medical Systems, a Swedish developer of the Baha system, for approximately A$195 million in March 2005. This purchase expanded Cochlear's portfolio beyond cochlear implants to include solutions, leveraging Entific's established technology rooted in research initiated in 1977 by Per-Ingvar Brånemark and colleagues at the . The Baha system became commercially available in 1987 and received U.S. approval for conductive and mixed in 1996, with extension to single-sided deafness in 2002. The Cochlear Baha system transmits sound vibrations directly to the via , bypassing the outer and , making it suitable for individuals with , mixed hearing loss, or single-sided where traditional air conduction aids are ineffective. It consists of a surgically implanted fixture that osseointegrates with the behind the , connected either via a (Baha Connect) or magnetically across intact skin (Baha Attract). Sound processors, such as the Baha 7 introduced in June 2025, feature a compact with a 55 dB HL fitting range, LE Audio compatibility, and Auracast support for streaming from compatible devices. Non-surgical options like the Baha Start kit allow trial of without implantation, using adhesive or softband attachments. Advancements in Baha processors have emphasized improved sound processing in noise, smaller form factors, and user connectivity. The Baha 5 Sound Processor, launched in April 2015, incorporated wide and true wireless streaming to enhance speech clarity in challenging environments. Subsequent iterations, including the Baha 6 Max in 2021, focused on maximizing output for severe losses while maintaining discretion. Clinical studies indicate Baha users experience significant improvements in and compared to conventional aids, particularly for conductive losses, though outcomes vary by patient and loss severity.

Auditory Brainstem Implants (ABI)

Cochlear Limited's Auditory Brainstem Implant (ABI) systems provide auditory rehabilitation for patients with profound bilateral ineligible for cochlear implants due to auditory nerve avulsion or destruction, most commonly from type 2 (NF2) tumors requiring surgical resection. These devices electrically stimulate the in the lateral recess of the , bypassing the and auditory nerve to elicit auditory sensations. Unlike cochlear implants, which target the neurons, ABIs interface directly with the , necessitating neurosurgical implantation often during tumor removal procedures. The Nucleus 24 ABI, Cochlear's initial commercial multichannel ABI, received U.S. (FDA) premarket approval in 2000 for individuals aged 12 years and older, building on earlier single-channel prototypes developed since the late 1970s at institutions like the House Ear Institute. This system featured 21 active electrodes on a flat paddle array positioned over the , paired with external speech processors compatible with Cochlear's Nucleus platform for . Implantation typically occurs via retrosigmoid , with the electrode secured to avoid migration, and activation follows 4-6 weeks post-surgery to allow tissue stabilization. In June 2016, the FDA approved the Nucleus ABI541 as a supplemental modification to the ABI24M, incorporating design enhancements for improved tissue contact, MRI compatibility up to 1.5 Tesla without magnet removal, and integration with contemporary Nucleus sound processors like the CP910 series. The ABI541 maintains the 21-electrode configuration but optimizes positioning for better spectral coverage, with capabilities for intraoperative neural response monitoring to verify contact with the . Cochlear reports over 1,000 ABI implantations worldwide by the mid-2010s, primarily in NF2 patients, though expanded indications include bilateral auditory neuropathy or cochlear in select cases. Clinical outcomes with Cochlear ABIs demonstrate restoration of non-linguistic environmental sound awareness in 80-90% of users, but remains limited, with open-set sentence recognition averaging 20-40% in quiet conditions for post-lingually deafened adults, inferior to performance due to broader current spread and less tonotopic organization in stimulation. Pediatric applications, though off-label under initial FDA indications, have shown variable progress, with early implantation yielding better auditory-oral in non-NF2 cases via neural plasticity. Long-term studies indicate device reliability exceeding 95% at 5 years, with complications including stimulation (10-20%) managed via reprogramming, underscoring the need for specialized multidisciplinary teams.

Technological Advancements and Research

Research and Development Focus

Cochlear Limited invests approximately 12% of its annual revenue in research and development, totaling over $290 million in fiscal year 2025, to advance implantable hearing solutions for severe to profound sensorineural hearing loss. This funding prioritizes enhancements in hearing outcomes, including superior speech perception via refined signal processing algorithms and neural stimulation techniques that adapt to individual auditory nerve responses. Clinical studies supported by the company examine input processing strategies, such as noise reduction and directional microphones, to optimize performance in complex acoustic environments. A core focus involves hearing preservation and electro-acoustic stimulation (EAS), targeting patients with residual low-frequency hearing by developing arrays that minimize trauma to the cochlea's inner structures. Research extends to expanding implantation indications, particularly in , where efforts address neurocognitive development and long-term outcomes through early intervention protocols. Innovations in and design, such as thinner, flexible arrays compatible with MRI imaging up to 3 tesla, aim to reduce surgical risks and improve post-operative safety. The company integrates emerging technologies like for predictive sound coding and firmware-upgradable implants, as demonstrated by the 2025 Nexa System, which enables remote software updates to deliver future enhancements without hardware replacement. Strategic partnerships, including an expanded 2025 collaboration with GN, pool R&D resources to create AI-enhanced platforms for personalized hearing profiles across implants and accessories. Ecosystem connectivity receives attention through compatibility with devices from Apple, Android, and ReSound, facilitating seamless data sharing for rehabilitation apps and tele-audiology. Additional priorities encompass user-centric design, such as off-the-ear processors for comfort and for active lifestyles, alongside efforts to lower barriers to care via cost-effective and global clinical trials validating efficacy in diverse populations. These initiatives align with establishing cochlear implantation as the standard for eligible patients, supported by ongoing investments in bone-anchored and implant refinements.

Major Innovations and Patents

Cochlear Limited's foundational innovation was the commercialization of the multi-channel , which advanced beyond single-channel systems by delivering electrical stimulation to multiple electrodes along the , improving speech discrimination for profoundly deaf individuals. This technology, developed from research by Graeme Clark at the , culminated in the Nucleus 22 device, with the first human implantation occurring in 1978 and commercial availability following FDA approval as the world's first multi-channel implant in 1985. Subsequent advancements included the introduction of hybrid electro-acoustic stimulation (EAS) systems, combining electrical stimulation for high-frequency hearing loss with acoustic amplification for preserved low-frequency hearing, as seen in devices like the Nucleus Hybrid, enabling better music perception and speech understanding in noise. In bone conduction, the Osia System employed piezoelectric transduction for direct skull vibration, offering improved sound transmission efficiency over traditional magnetic systems, with clinical data showing gains in speech recognition scores of up to 20-30% in quiet environments. Cochlear maintains a robust portfolio exceeding 3,200 filings globally, with approximately 1,664 granted and over 44% active as of recent analyses, concentrating on algorithms for , electrode array designs for atraumatic insertion, and implantable battery integration for extended device longevity. Key early s include US4532930A (1985), detailing a multi-electrode cochlear system emphasizing speech communication via current steering techniques. More recent protections cover advancements like programmable accessory interfaces for cochlear implants, enhancing post-operative customization and remote monitoring capabilities.

Controversies and Regulatory Issues

Product Recalls and Safety Concerns

In September 2011, Cochlear Limited initiated a voluntary global recall of its unimplanted Nucleus CI500 series cochlear implants, including models CI512, CI513, and CI532, due to a manufacturing defect in the that allowed moisture ingress, potentially causing the device to fail and cease functioning. The issue stemmed from a fault in the feedthrough assembly, leading to and short-circuiting; while the recall targeted unimplanted units, approximately 4,200 implanted devices worldwide were affected, with the company offering monitoring, reprogramming, or explantation options for patients experiencing failures. This event resulted in a sharp decline in Cochlear's share price, erasing about A$835 million ($835 million) in market value on the announcement day. Earlier, in November 2009, the U.S. (FDA) classified a Class 2 recall for Cochlear's Nucleus Non-Magnetic Plug (REF Z50100), a sterile component used in removable magnet implants, due to potential packaging integrity issues that could compromise sterility. Additional recalls have involved sound processors and accessories, such as those linked to moisture-related seal defects in various implant models, prompting FDA warnings about premature device failure. Safety concerns with Cochlear implants have centered on device reliability and compatibility with medical imaging. The FDA has highlighted risks during magnetic resonance imaging (MRI), including magnet displacement, pain, heating, or torque on the internal magnet, particularly in older or non-MRI-conditional models, advising patients to discuss precautions like magnet removal with providers. Manufacturer and User Facility Device Experience (MAUDE) database reports for Cochlear Nucleus devices document adverse events such as implant pain, non-auditory sensations, poor performance, and explantations due to failure or MRI incompatibility, with some cases linked to corrosion or communication loss between components. Earlier models, like certain Nucleus 24 variants, faced scrutiny for elevated bacterial meningitis risk in pediatric users, prompting FDA public health notifications in 2002 and enhanced labeling requirements. Post-recall reliability data from Cochlear indicates cumulative survival rates for newer series exceeding 99% at five years, though the company acknowledges ongoing risks of device malfunction or patient injury, with voluntary reporting to regulators. Regulatory bodies continue to monitor these implants for long-term adverse events, emphasizing the need for vigilant post-market given the permanent implantation nature. In 2010, Cochlear Americas, a of Cochlear Limited, settled allegations under the False Claims Act for $880,000 with the U.S. Department of Justice, resolving claims that the company violated the Anti-Kickback Statute by providing remuneration to physicians, including free products, training, and consulting fees, to induce purchases and implantation of its cochlear devices reimbursed by federal healthcare programs such as Medicare and . The lawsuit, originally filed under the provisions by a whistleblower in the U.S. District Court for the District of , highlighted non-monetary inducements disguised as legitimate business practices, which federal regulators deemed improper under statutes prohibiting kickbacks in federally funded healthcare. Cochlear did not admit liability in the settlement but agreed to the payment and enhanced internal compliance measures to prevent future violations. Cochlear Limited has faced multiple lawsuits in the United States, resulting in significant financial penalties for willful violations. In a high-profile case initiated by the Foundation, a U.S. district in 2020 ordered Cochlear to pay $280 million in damages plus $75 million in legal fees after finding infringement of patents related to telemetry and stimulation technologies, with enhanced damages due to evidence of deliberate copying and failure to obtain opinions of counsel. The U.S. denied in 2021, upholding the award, which stemmed from Cochlear's importation and sale of devices incorporating the patented features without licensing. Earlier in the dispute, a 2018 ruling enhanced damages to $268 million based on similar findings of willfulness. Compliance challenges have also arisen in international trade regulations, including a 2024 U.S. International Trade Commission investigation under Section 337 of the Tariff Act of 1930 into allegations that certain Cochlear cochlear implant systems infringe U.S. patents through importation and domestic sales, potentially leading to exclusion orders if violations are confirmed. These proceedings underscore ongoing scrutiny of Cochlear's global supply chain and intellectual property practices, though no final determination of violation has been issued as of October 2025. In response to such issues, Cochlear has invested in compliance frameworks, including ISO/IEC 27001 certification for information security in 2023, aimed at mitigating risks in regulatory and data handling environments.

Labor and Union Disputes

In the mid-2000s, Cochlear Limited encountered regulatory hurdles in implementing individual Australian Workplace Agreements (AWAs) for its approximately 300 Sydney-based manufacturing employees, as the Australian Industrial Relations Commission rejected the company's appeal to override collective terms from prior agreements. By October 2007, the Australian Manufacturing Workers' Union (AMWU) alleged that Cochlear threatened disciplinary action against workers speaking languages other than English at its Lane Cove plant, prompting union complaints to regulators; the company countered that the claims were exaggerated and constituted a union-orchestrated beat-up to stir unrest. A protracted dispute emerged in when Cochlear's manufacturing workers, amid the transition to Labor's Fair Work Act, voted over 95% in favor of a union in multiple ballots, rejecting the company's proposed non-union enterprise agreement that offered limited wage increases and flexibility provisions tailored to high-precision implant production. The AMWU accused Cochlear of union-busting by prioritizing individual or non-union arrangements to maintain operational agility in a specialized sector, while the company argued that union demands risked in its global . The conflict intensified through 2011, with Fair Work Australia (FWA) issuing good faith bargaining orders against Cochlear in December for breaches including inadequate information sharing and failure to substantively engage on key proposals, marking a rare enforcement under the Act's bargaining rules. The AMWU filed further appeals citing Cochlear's resistance to concessions on wages, rosters, and redundancy protections, leading the company to launch separate legal proceedings against the union for alleged in negotiations. In AMWU v Cochlear Limited FWA 5374, FWA Commissioner Cargill scrutinized the company's tactics post-orders, concluding that Cochlear had undermined collective processes through selective concessions and delays, though unions characterized the ruling as a limited victory amid ongoing impasse. No strikes materialized, but the episode highlighted tensions between union representation and employer demands for flexibility in Australia's evolving industrial framework; subsequent enterprise agreements appear to have stabilized relations, with no major public disputes reported after 2012.

Achievements and Societal Impact

Clinical Efficacy and User Outcomes

Cochlear implants developed by Cochlear Limited, particularly the Nucleus system, enable significant restoration of auditory function in individuals with severe to profound by directly stimulating the auditory nerve, bypassing damaged cochlear hair cells. Clinical trials have demonstrated marked improvements in ; for instance, in a multicenter study of the Nucleus 6 system, 82% of recipients showed enhanced performance in quiet environments and 74% in noisy conditions following implantation. Similarly, evaluation of the Nucleus 5 system revealed substantial gains in open-set sentence recognition, with average scores increasing from pre-implant levels of around 20-30% to over 70% post-implantation in controlled settings. These outcomes vary based on factors such as age at implantation and residual hearing, but empirical data consistently indicate superior auditory thresholds compared to conventional hearing aids for eligible candidates. In pediatric users, early implantation with Nucleus devices correlates with accelerated and auditory skill development. A study of children implanted between 9 and 11 months of age reported safe surgical outcomes and rapid progress in babble and within the first year, underscoring the benefits of neural plasticity in infancy. Long-term follow-up of adolescents implanted as children showed sustained advantages, including higher rates of mainstream education and telephone use proficiency, with statistical significance over later-implanted peers. For adults, particularly older recipients, Nucleus implants yield clinically meaningful elevations in speech intelligibility, with consonant-nucleus-consonant word scores stabilizing or improving beyond the first year of use. User-reported quality-of-life metrics further affirm efficacy, with reductions in isolation and depressive symptoms post-implantation. In older adults, cochlear implantation led to enhanced social participation and self-perceived health status, as measured by standardized scales like the Health Utilities Index. Long-term data from users with high-frequency indicated that 94% retained measurable auditory benefit and 72% persisted with electric-acoustic stimulation after five years, reflecting durability of outcomes. Bilateral implantation with Nucleus systems additionally improves localization and noise tolerance over unilateral use, though evidence quality for some metrics remains moderate due to study designs. Variability persists, with non-auditory factors like cognitive status influencing ultimate gains, yet aggregate results support implantation as a causal intervention for functional hearing restoration.

Awards, Recognition, and Industry Leadership

Cochlear Limited maintains a dominant position in the market, holding over 60% global as of 2025, driven by its extensive portfolio of implantable hearing solutions and more than 550,000 devices implanted worldwide. The company leads in , with consistent recognition as the top manufacturer in the sector, outpacing competitors like and Advanced Bionics, which together hold the remaining major shares. This leadership stems from pioneering multi-channel technology since the , enabling the company to support the majority of global hearing implant recipients. In terms of awards, Cochlear was ranked the world's most trustworthy healthcare company by in its 2024 survey of global brands, based on consumer trust metrics and stakeholder evaluations. Cochlear received dual gold awards at the 2025 Hearing & Technology Matters Innovator Awards for advancements in hearing care and progression. Earlier, in 2023, its Osia OSI300 implant earned an Innovator Award as the first MRI-safe active system. The company also secured a Gold German Brand Award for Industry Excellence in Branding within the & category, affirming its branding strength in Europe. Additional recognitions include a Silver Award from Cigna's 2025 Healthy Workforce Designation for employee wellness programs encompassing mental health and fitness initiatives. In 2013, Cochlear won four international design awards for product innovations, highlighting its early focus on user-centric design in hearing devices. These accolades underscore Cochlear's sustained emphasis on technological reliability and patient outcomes, though industry analysts note that market leadership metrics prioritize implant volume and R&D investment—12% of revenue in FY25—over subjective trust rankings.

Economic and Global Contributions

Cochlear Limited, headquartered in , , plays a pivotal role in the national economy as a leading exporter of advanced medical devices, with less than 5% of its sales sourced domestically and the remainder derived from international markets. In fiscal year 2025, the company achieved sales of AUD 2.356 billion, a 4% increase from the prior year, primarily driven by exports of cochlear implants and related technologies, thereby bolstering Australia's in high-value sectors. As one of Australia's top 30 listed companies by , exceeding AUD 15 billion as of 2023, Cochlear sustains domestic and ecosystems through its operations, including significant R&D expenditures of AUD 292 million in FY25—equivalent to 12% of —which support skilled jobs and technological spillovers in the medtech industry. On a global scale, Cochlear commands over 60% in cochlear implants, positioning it as the dominant player in implantable hearing solutions and enabling widespread adoption of its technologies across diverse economies. The company distributes products in more than 180 countries, maintains direct operations in over 30, and employs around 5,500 personnel worldwide as of June 2025, with manufacturing sites in , , , and that integrate into international supply chains and generate local economic activity. These efforts have provided over 700,000 devices globally since 1981, enhancing workforce participation and reducing long-term healthcare costs in recipient nations by addressing severe-to-profound through reliable, evidence-based interventions.

References

  1. https://finance.yahoo.com/quote/COH.AX/profile/
  2. https://www.cochlear.com/uk/en/about-us/proven-over-time
  3. https://www.cochlear.com/au/en/about-us
  4. https://assets.cochlear.com/api/public/content/3e225db043454396ba51833daf34b7c5?v=dbdf09d3
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC6913847/
  6. https://lemelson.mit.edu/resources/graeme-clark
  7. https://www.nhmrc.gov.au/about-us/resources/impact-case-studies/cochlear-implant-restores-hearing
  8. https://www.cochlear.com/us/en/about-us
  9. https://www.morningstar.com/stocks/xasx/coh/quote
  10. https://www.researchgate.net/figure/The-one-million-cochlear-implant-market-share-Cochlear-Limited-is-the-largest_fig1_362329372
  11. https://rogermontgomery.com/cochlears-financial-year-2025-results-and-outlook-for-financial-year-2026/
  12. https://www.listcorp.com/asx/coh/cochlear-limited/news/fy24-result-asx-and-amp-media-release-3069001.html
  13. https://www.intelligentinvestor.com.au/shares/asx-coh/cochlear-limited/financials
  14. https://www.marketsandmarkets.com/Market-Reports/cochlear-implants-market-94935516.html
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4391344/
  16. https://www.encyclopedia.com/books/politics-and-business-magazines/cochlear-ltd
  17. https://hearandnow.cochlear.com/hearing-solutions/bone-conduction/evolution-of-baha/
  18. https://www.prnewswire.com/apac/news-releases/cochlear-celebrates-30-years-in-china-and-the-launch-of-the-worlds-first-and-only-smart-hearing-implant-system-302486798.html
  19. https://www.cochlear.com/uk/en/corporate/media/media-releases/2017/2017-07-13-cochlear-to-expand-global-capacity-with-china-manufacturing-facility
  20. https://www.mida.gov.my/media-release/cochlear-expands-global-operations-and-manufacturing-in-malaysia-helping-thousands-to-hear-better/
  21. https://assets.cochlear.com/api/public/content/b3efa85f4610471da3400dab61af6f64?v=8049f6ff
  22. https://www.cochlear.com/us/en/corporate/investors/corporate-information/board-of-directors
  23. https://assets.cochlear.com/api/public/content/80e3d785f3604cefad95a1368d9417a8?v=cb051d5b
  24. https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/management
  25. https://www.cochlear.com/us/en/corporate/investors/corporate-information/executive-team
  26. https://www.listcorp.com/asx/coh/cochlear-limited/news/cochlear-announces-changes-to-the-executive-team-3060156.html
  27. https://amtil.com.au/cochlear-opens-new-manufacturing-facility-in-queensland/
  28. https://www.cochlear.com/sv/se/corporate/media/media-releases/2017/2017-07-13-cochlear-to-expand-global-capacity-with-china-manufacturing-facility
  29. https://assets.cochlear.com/api/public/content/1b9dbdf9214c429e817f2e2eef1ec719?v=66737e32
  30. https://announcements.asx.com.au/asxpdf/20250815/pdf/06mwwc8bndj71z.pdf
  31. https://www.cochlear.com/us/en/home/products-and-accessories/cochlear-nucleus-system
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4111375/
  33. https://www.cochlear.com/us/en/professionals/products-and-candidacy/nucleus
  34. https://www.accessdata.fda.gov/cdrh_docs/pdf/P970051S205D.pdf
  35. https://www.accessdata.fda.gov/cdrh_docs/pdf/P970051S172C.pdf
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4921065/
  37. https://www.afr.com/companies/cochlear-expands-reach-with-entific-buy-20050305-jl67s
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3068630/
  39. https://www.optecoto.com/article/S1043-1810%2810%2900018-7/fulltext
  40. https://www.cochlear.com/us/en/home/products-and-accessories/cochlear-baha-system
  41. https://www.cochlear.com/us/en/professionals/products-and-candidacy/baha
  42. https://www.cochlear.com/us/en/corporate/media-center/media-releases/2025/cochlear-introduces-the-baha-7-sound-processor-and-baha-soundband
  43. https://www.prnewswire.com/news-releases/cochlear-launches-industrys-smallest-bone-conduction-sound-processor-with-innovative-technologies-designed-to-make-listening-easier-300062154.html
  44. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P000015
  45. https://www.accessdata.fda.gov/cdrh_docs/pdf/P000015c.pdf
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC6361749/
  47. https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/2024/March/PRV_Audit_Brainstem_Implant.pdf
  48. https://www.premera.com/medicalpolicies/7.01.83.pdf
  49. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P000015S012
  50. https://clinicaltrials.gov/study/NCT01864291
  51. https://oto.wustl.edu/patient-care/ear-hearing/auditory-brainstem-implants/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC6438789/
  53. https://assets.cochlear.com/api/public/content/d619dbed86084a98abb6298c6c02cec1?v=62105341
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8476711/
  55. https://www.cochlear.com/us/en/professionals/cochlear-partnerships/clinical-studies
  56. https://pronews.cochlear.com/reliability-reporting-setting-a-new-standard-with-ansi-aami-ci862017/
  57. https://www.cochlear.com/us/en/corporate/media-center/media-releases/2025/cochlear-launches-worlds-first-and-only-smart-cochlear-implant-system
  58. https://www.audiologyonline.com/releases/cochlear-and-gn-expand-r-29301
  59. https://www.cochlear.com/us/en/about-us/driving-progress
  60. https://www.annualreports.com/HostedData/AnnualReportArchive/C/ASX_COH_2023.pdf
  61. https://www.cochlear.com/mics/531f58d9-011d-48a7-81d6-1fd7c1ea1311/2019StrategyOverview.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE-531f58d9-011d-48a7-81d6-1fd7c1ea1311-mOnW4K
  62. https://pronews.cochlear.com/science-behind-cochlear-osia-system/
  63. https://insights.greyb.com/cochlear-patents/
  64. https://patents.google.com/patent/US4532930A/en
  65. https://ir.envoymedical.com/news-events/press-releases/detail/57/envoy-medical-secures-four-new-global-patents-expanding-its-leadership-position-in-fully-implantable-hearing-technology
  66. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=104183
  67. https://www.tga.gov.au/safety-and-shortages/market-actions/cochlear-nucleus-ci500-implant-range-recall-notice
  68. https://www.biospace.com/product-recall-wipes-835-million-off-cochlear-limited-s-value
  69. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?start_search=1&pnumber=P970051
  70. https://www.millerandzois.com/products-liability/medical-device-lawsuits/other-medical-devices/cochlear/
  71. https://www.fda.gov/medical-devices/cochlear-implants/cochlear-implants-and-mri-safety
  72. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=12552136&pc=MCM
  73. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=20793699&pc=MCM
  74. https://leader.pubs.asha.org/doi/10.1044/leader.FTR4.11052006.5
  75. https://pronews.cochlear.com/wp-content/uploads/2025/06/D2325238-V1-05_EN_Cochlear_Nucleus_Reliability_Report.pdf
  76. https://www.fda.gov/medical-devices/implants-and-prosthetics/cochlear-implants
  77. https://www.justice.gov/archives/opa/pr/united-states-settles-false-claims-act-allegations-cochlear-americas-880000
  78. https://www.afr.com/companies/healthcare-and-fitness/cochlear-loses-final-appeal-hope-in-patent-infringement-damages-20201215-p56npt
  79. https://www.supremecourt.gov/DocketPDF/20/20-362/153945/20200914162837813_20-__PetitionForAWritOfCertiorari.pdf
  80. https://www.reuters.com/article/business/healthcare-pharmaceuticals/cochlear-asked-to-pay-268-mln-in-us-patents-lawsuit-idUSL4N1XF0SL/
  81. https://www.federalregister.gov/documents/2024/09/23/2024-21634/certain-cochlear-implant-systems-and-components-thereof-notice-of-institution-of-investigation
  82. https://www.usitc.gov/press_room/news_release/2024/er0917_65912.htm
  83. https://www.cochlear.com/nl/nl/corporate/media/media-releases/2023/2023-01-30-cochlear-is-first-hearing-implant-manufacturer-to-receive-certification
  84. https://www.abc.net.au/listen/programs/pm/hearing-implant-company-cochlear-loses-appeal-in/275594
  85. https://www.abc.net.au/news/2007-10-31/english-only-complaint-a-union-beat-up-cochlear/712396
  86. https://www.actu.org.au/media-release/cochlear-workers-vote-for-new-collective-agreement-time-for-company-to-negotiate/
  87. https://www.industriall-union.org/archive/imf/cochlear-workers-fight-for-union-representation-0
  88. https://www.afr.com/policy/economy/workplace-risks-magnified-for-cochlear-20090811-jn4n2
  89. https://www.workplaceexpress.com.au/news/fwa-issues-bargaining-orders-against-cochlear-48668
  90. https://www.afr.com/policy/economy/cochlear-deaf-to-unions-20111215-jj7ew
  91. https://www.theaustralian.com.au/nation/cochlear-hits-back-in-union-battle/news-story/ebed6f0547653e4d812e9556b56a92dd
  92. https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Education_and_Employment/AvoidanceofFairWork/~/media/Committees/eet_ctte/AvoidanceofFairWork/c03.pdf
  93. https://www.theaustralian.com.au/nation/politics/unions-modest-win-in-cochlear-dispute/news-story/1aab5c687f5073650c3c7789d3af5b92
  94. https://pronews.cochlear.com/wp-content/uploads/2015/07/Roland_et_al-2015-The_Laryngoscope.pdf
  95. https://pubmed.ncbi.nlm.nih.gov/27310402/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC3262414/
  97. https://journals.sagepub.com/doi/10.1177/23312165241261480
  98. https://www.frontiersin.org/journals/rehabilitation-sciences/articles/10.3389/fresc.2023.1275808/full
  99. https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/1671204
  100. https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2769939
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC6792393/
  102. https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/1655350
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC11932275/
  104. https://mss-p-007-delivery.sitecorecontenthub.cloud/api/public/content/baf7f33ae2ed4cec986b655891131e5d?v=30a1aa0f
  105. https://www.marketsandmarkets.com/ResearchInsight/cochlear-implants-market.asp
  106. https://www.prnewswire.com/news-releases/cochlear-named-most-trustworthy-healthcare-company-in-the-world-302389010.html
  107. https://www.cochlear.com/us/en/corporate/media-center/media-releases/2025/cochlear-north-america-wins-dual-honors-at-2025-hearing-health-and-technology-matters-innovator-awards
  108. https://www.cochlear.com/us/en/corporate/media-center/media-releases/2023/cochlears-osia-osi300-implant-wins-innovator-award
  109. https://policycommons.net/artifacts/13956099/cochlear-unter-den-besten-der-deutschen-markenlandschaft/14853925/
  110. https://www.cochlear.com/us/en/corporate/media-center/media-releases/2025/honored-with-silver-award-from-cignas-healthy-workforce-designation
  111. https://finance.yahoo.com/news/cochlear-limited-wins-four-awards-050000266.html
  112. https://www.cochlear.com/au/en/corporate/careers/cochlear-culture
  113. https://stockanalysis.com/quote/otc/CHEOF/employees/
  114. https://www.globaldata.com/company-profile/cochlear-ltd/
Add your contribution
Related Hubs
User Avatar
No comments yet.